Qu Mingzi, Lu Ping, Lifshitz Lawrence M, Moore Simas Tiffany A, Delpapa Ellen, ZhuGe Ronghua
Department of Microbiology and Physiological Systems, UMass Chan Medical School, 363 Plantation St., Worcester, MA, USA.
Program in Molecular Medicine, UMass Chan Medical School, 373 Plantation St., Worcester, MA, USA.
Eur J Pharmacol. 2024 Apr 5;968:176343. doi: 10.1016/j.ejphar.2024.176343. Epub 2024 Jan 26.
Uterine contractions during labor and preterm labor are influenced by a complex interplay of factors, including hormones and inflammatory mediators. This complexity may contribute to the limited efficacy of current tocolytics for preterm labor, a significant challenge in obstetrics with 15 million cases annually and approximately 1 million resulting deaths worldwide. We have previously shown that the myometrium expresses bitter taste receptors (TAS2Rs) and that their activation leads to uterine relaxation. Here, we investigated whether the selective TAS2R5 agonist phenanthroline can induce relaxation across a spectrum of human uterine contractions and whether the underlying mechanism involves changes in intracellular Ca signaling. We performed experiments using samples from pregnant women undergoing scheduled cesarean delivery, assessing responses to various inflammatory mediators and oxytocin with and without phenanthroline. Our results showed that phenanthroline concentration-dependently inhibited contractions induced by PGF2α, U46619, 5-HT, endothelin-1 and oxytocin. Furthermore, in hTERT-infected human myometrial cells exposed to uterotonics, phenanthroline effectively suppressed the increase in intracellular Ca concentration induced by PGF2α, U46619, oxytocin, and endothelin-1. These results suggest that the selective TAS2R5 agonist may not only significantly reduce uterine contractions but also decrease intracellular Ca levels. This study highlights the potential development of TAS2R5 agonists as a new class of uterine relaxants, providing a novel avenue for improving the management of preterm labor.
分娩和早产期间的子宫收缩受多种因素的复杂相互作用影响,包括激素和炎症介质。这种复杂性可能导致目前用于早产的宫缩抑制剂疗效有限,这是产科领域的一个重大挑战,每年有1500万例早产病例,全球约有100万例导致死亡。我们之前已经表明,子宫肌层表达苦味受体(TAS2Rs),其激活会导致子宫松弛。在此,我们研究了选择性TAS2R5激动剂菲咯啉是否能在一系列人类子宫收缩中诱导松弛,以及潜在机制是否涉及细胞内钙信号的变化。我们使用计划剖宫产的孕妇样本进行实验,评估在有和没有菲咯啉的情况下对各种炎症介质和催产素的反应。我们的结果表明,菲咯啉浓度依赖性地抑制了PGF2α、U46619、5-羟色胺、内皮素-1和催产素诱导的收缩。此外,在暴露于宫缩剂的hTERT感染的人子宫肌层细胞中,菲咯啉有效地抑制了PGF2α、U46619、催产素和内皮素-1诱导的细胞内钙浓度升高。这些结果表明,选择性TAS2R5激动剂不仅可能显著减少子宫收缩,还可能降低细胞内钙水平。这项研究突出了TAS2R5激动剂作为一类新型子宫松弛剂的潜在开发,为改善早产管理提供了一条新途径。